


SUPPLEMENTAL FIGURES



Supplemental Figure 1. Tumor mutation burden (TMB) per subtype (left) and BRCA2 somatic mutation or deep deletion status per subtype (right). No significant differences were found between the subtypes, but the TMB was highest in the adeno-immune subtype, consistent with a higher immune response. TMB is defined per cBioPortal, and only shown for WCM, FHCRC, and the ECDT cohorts, and not for the WCDT as this was the only whole-genome sequencing (WGS) cohort, which may not be directly comparable with exome sequencing.